Project Grant R41DK142265
Award Date
7/25/25
Completion Date
7/24/26
Dollars Obligated
$350K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Evanston, IL 60201, USA
Similar Awards
This $310,897 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a first-in-class, islet-targeted antibody therapeutic for Type 1 Diabetes (T1D). The award supports preclinical development and validation activities for this novel antibody therapy, including establishing proof-of-principle for its islet-homing capability, therapeutic...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Qrono, Inc., a for-profit medical research and development company. The grant funding supports the development of QR402, a first-in-class, oral nanomedicine that uses an AMPK pathway agonist to target intestinal dendritic cells and restore immunological tolerance as a preventative therapy for type 1 diabetes. The goal is to...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $298,364 in funding to Immunoshield Therapeutics Inc. to investigate optimal islet density and dosage within macroencapsulation devices for clinical islet transplantation to treat type 1 diabetes. The research aims to address limitations in current macroencapsulation approaches, such as...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...
The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
This Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), focuses on investigating the role of lymph node stromal cells in maintaining peripheral tolerance and reducing autoimmunity in type 1 diabetes. The primary awardee, The Trustees of Columbia University in the City of New York, will receive $602,531 to conduct research aimed at: Evaluating...
This $300,000 federal Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to engineer human regulatory T cells (Tregs) with a chimeric antigen receptor (CAR) targeting NTPDase3 on B cells for controlling type 1 diabetes (T1D). The project, led by Sanford Research, will test CAR Tregs with varying antigen binding affinities to optimize their activation, proliferation, and suppressive function against islet-reactive T...
This Project Grant awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $275,000 in funding to Islex Therapeutics, LLC to develop antibody therapeutics for the treatment of stage 3 type-1 diabetes (T1D). The project aims to harness the synergistic effects of autoimmune protection, insulin supplementation, and targeted delivery of mitogenic drugs to the pancreatic islet, the disease site of T1D. The research...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $380,000 to the University of Miami to develop a bifunctional RNA therapeutic called PS03. The goal is to use PS03 to modulate PD-L1 expression specifically on B cells in order to induce T cell exhaustion and halt the autoimmune attack in type 1 diabetes. The award period runs from August 1, 2025 to July 31, 2026....